Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine

San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $15 million grant to support the expanded clinical development of ISP-001, its lead investigational therapy for the treatment of mucopolysaccharidosis type I (MPS I), a rare and life-threatening lysosomal storage disorder.

“There is no cure for MPS I, and there is a significant unmet need for therapies that can deliver meaningful functional improvements for patients,” said Sean Ainsworth, Chief Executive Officer of Immusoft. “ISP-001 has shown early signs of functional improvement and reductions in pain, highlighting its potential for long-term, continuous therapeutic protein delivery that may avoid many of the limitations of other approaches being developed. We are grateful for our ongoing partnership with CIRM and look forward to advancing this candidate, including into pediatric patients.” Read More>>